Abstract
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disease
caused by Aspergillus induced hypersensitivity that occurs in
immunocompetent but susceptible patients with asthma and/or cystic
fibrosis (CF). In children, ABPA remains mostly undiagnosed, resulting
in one of the most common causes of poorly controlled asthma and highly
significant morbidity in children with CF. Currently, no specific
diagnostic criteria of ABPA for children are available. Corticosteroids
and itraconazole are the mainstays of therapy, althoughthere is a lack
of randomized clinical trials regarding their usefulness for ABPA in
children. Several monoclonal antibodies, such asomalizumab and
mepolizumab, may be potential therapies for refractory ABPA in pediatric
patients; however, further data are required to clarify the optimal dose
and duration of therapy as a routine treatment approach.